Iron showdown: which anemia drug works best for kidney patients?
NCT ID NCT06994065
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 128 adults with chronic kidney disease (not on dialysis) who also had iron-deficiency anemia. Researchers compared two intravenous iron treatments—ferric carboxymaltose and iron sucrose—to see which raises hemoglobin and iron levels better and with fewer side effects. Participants received a dose based on their iron deficit and were followed for 56 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ferric carboxymaltose (FCM) and iron sucrose
- What this could lead to
- If it works, this could point toward a more effective or convenient option for treating iron-deficiency anemia in people with chronic kidney disease who are not on dialysis.
- What could go wrong
- This is a small, completed trial (128 people) comparing two existing drugs, so it is not testing a new breakthrough. Results may not apply to all kidney patients, and both treatments carry risks like allergic reactions or low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IRON DEFICIENCY ANEMIA ASSOCIATED WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sindh Institute of Urology and Transplantaion
Karachi, Sindh, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.